Clean Science and Technology (CLEAN) Q2 25/26 earnings summary

Executive summary

• Standalone revenue declined 5% sequentially and 8% year-over-year to INR 206 crore, mainly due to lower sales in established products and competitive pressures from China.

• EBITDA margin remained strong at 44%, with a 2% year-over-year improvement due to favorable product mix and new product launches.

• Export revenues comprised 63% of consolidated revenues, reflecting a strong global presence.

• Standalone PAT was INR 65 crore, down 15% sequentially and 4% year-over-year, with a steeper decline than EBITDA due to forex losses.

• Approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.

Financial highlights

• Q2 FY2026 consolidated revenue was ₹245 crore, up 3% year-over-year; EBITDA margin at 41.7%.

• H1 FY2026 consolidated revenue grew 6% year-over-year to ₹488 crore; EBITDA margin at 38.9%.

• Standalone revenue from operations for H1 FY26 was ₹4,312.20 million, down from ₹4,453.74 million year-over-year.

• Standalone net profit for H1 FY26 was ₹1,412.09 million, compared to ₹1,395.93 million in H1 FY25.

• Health segment volumes grew over 25% sequentially, averaging 260 tons per month.

Outlook and guidance

• Management expects Q3 to remain flat, with growth anticipated in Q4 as new products contribute.

• Benefits of operating leverage expected as newly launched products scale in revenue.

• Board and management continue to focus on sustainability and innovation, with ongoing director appointments to strengthen governance.